Beck Mack & Oliver LLC Purchases New Position in Roche Holding AG $RHHBY

Beck Mack & Oliver LLC purchased a new stake in Roche Holding AG (OTCMKTS:RHHBY) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,626 shares of the company’s stock, valued at approximately $232,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Fulton Bank N.A. increased its stake in shares of Roche by 2.6% in the 1st quarter. Fulton Bank N.A. now owns 12,620 shares of the company’s stock valued at $518,000 after purchasing an additional 314 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Roche by 2.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,234 shares of the company’s stock valued at $668,000 after purchasing an additional 323 shares in the last quarter. Confluence Investment Management LLC increased its stake in Roche by 3.6% during the 1st quarter. Confluence Investment Management LLC now owns 14,491 shares of the company’s stock worth $596,000 after buying an additional 510 shares in the last quarter. Accent Capital Management LLC purchased a new stake in Roche during the 1st quarter worth approximately $35,000. Finally, North Star Asset Management Inc. increased its stake in Roche by 7.8% during the 1st quarter. North Star Asset Management Inc. now owns 17,305 shares of the company’s stock worth $712,000 after buying an additional 1,255 shares in the last quarter.

Roche Price Performance

OTCMKTS:RHHBY opened at $40.77 on Monday. Roche Holding AG has a 12 month low of $34.10 and a 12 month high of $44.31. The stock has a 50 day moving average of $40.08 and a two-hundred day moving average of $40.30. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 0.85.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.